Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» mirvetuximab soravtansine
mirvetuximab soravtansine
FDA bestows accelerated approval on ImmunoGen's ovarian cancer drug, with confirmatory answer coming soon
Endpoints
Tue, 11/15/22 - 10:41 am
Immunogen
FDA
ovarian cancer
mirvetuximab soravtansine
ImmunoGen commercial chief to withdraw before drug launch
Medical Marketing and Media
Fri, 11/4/22 - 10:27 am
Immunogen
mirvetuximab soravtansine
ovarian cancer
ImmunoGen Ovarian Cancer Drug Reaches BLA Milestone
BioSpace
Tue, 03/29/22 - 11:37 pm
Immunogen
ovarian cancer
FDA
mirvetuximab soravtansine
Immunogen's phase 3 ADC survival data spook investors, sending stock down ahead of FDA filing
Fierce Biotech
Mon, 03/21/22 - 10:17 am
Immunogen
mirvetuximab soravtansine
ovarian cancer
clinical trials
antibody-drug conjugate
ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial
Fierce Biotech
Tue, 11/30/21 - 10:29 am
Immunogen
mirvetuximab soravtansine
ovarian cancer
FDA
antibody-drug conjugate
ImmunoGen Plunges After Phase III Ovarian Cancer Treatment Fails to Hit PFS Endpoint
BioSpace
Fri, 03/1/19 - 10:16 am
Immunogen
ovarian cancer
clinical trials
mirvetuximab soravtansine
ImmunoGen Gets Good News From Interim Analysis of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
CP Wire
Fri, 04/27/18 - 01:18 pm
Immunogen
mirvetuximab soravtansine
ovarian cancer
platinum-resistant ovarian cancer
ImmunoGen Gets Good News From Interim Analysis of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
Fri, 04/27/18 - 01:19 pm
Immunogen
mirvetuximab soravtansine
ovarian cancer
platinum-resistant ovarian cancer